Published on : Jul 04, 2018
Albany, New York, July 4, 2018: Depression is a common and treatable mental health condition that can affect anyone. In this case, getting a prescription for depression drugs is something that many do because they want to seek help from their depression. Recently, Market Research Hub (MRH) has announced the inclusion of a study titled “Depression Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 – 2026”, to its massive repository, which suggests that rise in incidence of major depression disorders is projected to drive demand for depression drugs from 2018 to 2026.
This 288-page study encapsulates vital details about the global market covering its current market scenario as well as future status. Initially, the study comprises an exclusive summary, including a market snapshot that provides information on key segments. It also provides information and data analysis of the global market with respect to its segments based on drug class, disease type, distribution channel, and geography. The geographical segmentation of the report analyzes the scope of the market in different regions including North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Major Findings from the Report
- Depression is an indication where a patient feels down in the dumps, miserable, unhappy, blue, or sad. There are many types of treatment out there that are going to help people with their depression, and depression drugs are one of them. It has been clearly stated that increase in the prevalence of major depression disorders is projected to drive the market during the forecast period.
- Higher prevalence of depression was observed among female adults, which accounted for approximately 8.5% as against 4.8% among male adults in the U.S., according to the estimations of National Institute of Mental Health. Geographically, North America being the home company of many key players of the global depression drugs market is likely responsible for the governance of market share of the region.
- Besides, increase in government initiatives in creating awareness about depression drugs, and growth in geriatric population across the world is expected to drive the depression drugs market during the mentioned forecast period.
- Another vital section of the report outlines major drug classes, such as atypical antipsychotics, central nervous system (CNS) stimulant, serotonin-norepinephrine reuptake inhibitor, selective serotonin reuptake inhibitor, and others. By disease type, the study covers major depressive disorder, schizophrenia and bipolar I disorder, selective serotonin reuptake inhibitor induced, and others.
The report concludes with the profiles of major players in the global depression drugs market such as AstraZeneca, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Allergan USA, Inc., Novartis AG, Eli Lilly and Company, GlaxoSmithKline, and Takeda Pharmaceutical Company Ltd. Key players available in the market introduce their new depression drugs in developed regions such as Western Europe and North America. Hence, these regions are likely to account for significant share of the global depression drugs market.
Request a Sample with TOC in a PDF format : https://www.marketresearchhub.com/enquiry.php?type=S&repid=168173
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : email@example.com